Reference number
Coordinator Karolinska institutet - Institutionen för laboratoriemedicin, Novum
Funding from Vinnova SEK 1 500 000
Project duration September 2012 - March 2014
Status Completed

Purpose and goal

The aim of the project was to develop a novel BCG vaccine using a rational design. Most of the TB vaccines use secreted antigens. We identified three novel candidates that are responsible for the M tuberculosis cell wall development. Several recombinant BCG strains were constructed that express the cell-wall associated antigens (Rv0447c), Rv2957 and Rv2958c. Pre-clinical models were performed and immune responses were successfully tested, the antigens have been filed for IP to prepare for future trials.

Results and expected effects

Immune responses were successfully detected against the new TB vaccine targets. We have been able to show strong cellular and antibody responses against recombinant Rv0447c, Rv2957 and Rv2958c vaccine targets; particularly the target Rv2958c turned out to be superior in inducing T-cells producing interferon and TNFalpha. The recombinant BCG, expressing the new target antigens is available for phase I clinical trials.

Approach and implementation

Immunogenicity has been tested in animal models and using immune cells from patients with TB or from healthy donors. Expression of the new TB vaccine candidates in BCG has been tested by molecular biology and by specific antibodies that have been developed in our laboratory. Analysis of immune responses has been achieved by tetramer analysis, by cytokine production and by detection of vaccine target specific antibodies. We found that the vaccine construct is safe and immunogenic.

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 25 November 2019

Reference number 2012-03718

Page statistics